Compare RMT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMT | CTMX |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.7M | 716.9M |
| IPO Year | N/A | 2015 |
| Metric | RMT | CTMX |
|---|---|---|
| Price | $12.92 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $12.25 |
| AVG Volume (30 Days) | 86.5K | ★ 3.2M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.24 |
| P/E Ratio | ★ $8.86 | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.52 | $2.16 |
| 52 Week High | $14.78 | $8.21 |
| Indicator | RMT | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 38.82 |
| Support Level | $12.88 | $2.20 |
| Resistance Level | $14.32 | $2.61 |
| Average True Range (ATR) | 0.25 | 0.15 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 49.37 | 20.00 |
Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector, including diversified consumer services, hotels, household durables, leisure products, and luxury goods. Consumer staples sector, including beverages, food, and staples retailing, food products, and personal products, Energy sector, including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors, including healthcare, financials, industrials, IT, telecommunications, and materials.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.